Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06975059 · ClinicalTrials.gov registry record · NA

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

A NA study of Parkinson's Disease (PD), sponsored by Weill Medical College of Cornell University.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT06975059: Recruiting NA study of Parkinson's Disease (PD), sponsored by Weill Medical College of Cornell University.

NCT06975059 is a NA study of Parkinson's Disease (PD) that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 40 participants, below the 47-participant average among 4 other Parkinson's Disease (PD) trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06975059, a NA study of Parkinson's Disease (PD), is actively recruiting participants, sponsored by Weill Medical College of Cornell University.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe device, NUSHU by Magnes AG. The shoe additionally provides vibrational feedback that can potentially help gait difficulties experienced by Parkinson's patients.

Interventions

  • DEVICE NUSHU shoe

Study Locations (1)

New York

  • Weill Cornell - New York

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-05-30
Est. Completion 2030-07
Phase NA

What NCT06975059 shows while recruiting

NCT06975059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 47-participant average among 4 other Parkinson's Disease (PD) trials with a reported enrollment target (15% lower).

The record links to 1 condition, with Parkinson's Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which NUSHU shoe is the first listed.

NCT06975059 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06975059 about?

NCT06975059 is a clinical study titled "Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients". Gait changes in Parkinson's disease are complex, variable, and difficult to detect during short clinic assessments. The aim of this study is to collect gait measurements in Parkinson's patients through sensors in a novel shoe device, NUSHU by Magnes AG. The shoe additionally provides vibrational fee...

What is the current status of trial NCT06975059?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-05-30. Estimated completion is 2030-07.

What conditions does trial NCT06975059 study?

This clinical trial studies the following conditions: Parkinson's Disease (PD).

What interventions are being tested in trial NCT06975059?

The interventions under investigation include: NUSHU shoe (DEVICE).

Who is sponsoring clinical trial NCT06975059?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06975059 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease (PD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06975059, the US trial registry maintained by the National Library of Medicine. NCT06975059 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.